First-in-Human trial begins for new drug candidate

NCT ID NCT07046559

Recruiting now Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

Summary

This is an early-stage study to learn about the safety and side effects of a new drug called LY4066708 in healthy volunteers. Researchers will measure how much of the drug gets into the blood and brain and how long it stays in the body. The study will last up to 24 weeks and involves procedures like repeated lumbar punctures (spinal taps).

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fortrea Clinical Research Unit
RECRUITING

Holbeck, Leeds, LS11 9EH, United Kingdom

Contact Phone: •••-•••-••••

Contact

Conditions

Explore the condition pages connected to this study.

CANCER HEALTHY